이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

CAR-T 세포 관련 독성의 Emapalumab 예방

2026년 10월 1일 업데이트: Marcela V. Maus, M.D.,Ph.D.

CAR-T 세포 관련 독성 예방을 위한 Emapalumab의 2상 시험

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).

The research study involves the following study interventions:

  • Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
  • Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
  • Emapalumab

연구 개요

상세 설명

This is a phase 2 multi-center, open label study that is evaluating the safety and efficacy of emapalumab in preventing toxicities associated with FDA Approved, CD19-directed CAR-T in subjects with second- or third-line large B-cell non-Hodgkin's lymphoma.

A phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The U.S. Food and Drug Administration (FDA) has not approved emapalumab for the participants specific disease, but it has been approved for other uses.

The U.S. FDA has approved axicabtagene ciloleucel and lisocabtagene maraleucel for the participants specific disease.

This research study procedures include screening for eligibility, study treatment including collection of T cells (leukapheresis), lymphodepleting chemotherapy, treatment with emapalumab and axicabtagene ciloleucel or lisocabtagene maraleucel, and follow-up evaluations.

Once study treatment is completed, the participants will be followed for up to 24 months.

It is expected that about 28 people will take part in this research study.

연구 유형

중재적

등록 (추정된)

28

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • 모병
        • Massachusetts General Hospital
        • 수석 연구원:
          • Matthew Frigault, MD
        • 연락하다:
      • Boston, Massachusetts, 미국, 02215
        • 아직 모집하지 않음
        • Dana-Farber Cancer Institute
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Or adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

  • At least 1 measurable lesion per Lugano at time of screening.

  • Age 18 or older

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Adequate renal, hepatic, pulmonary and cardiac function defined as:

    • ANC ≥1000/uL
    • Platelet count ≥50,000/uL
    • Absolute lymphocyte count ≥100/uL
    • Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min
    • Serum ALT/AST ≤2.5 per institutional ULN
    • Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome.
    • Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings
    • Baseline oxygen saturation >92% on room air.
  • Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).

  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years.

  • Autologous stem cell transplant within 6 weeks of planned CAR-T infusion.

  • History of allogeneic stem cell transplantation.

  • Presence of uncontrolled fungal, bacterial, viral, or other infection at time of screening.

  • Known history of acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines.

    • Patients should also be negative for latent Tb, CMV (NAT), EBV (NAT) and adenovirus (NAT) by PCR testing.
  • No evidence of active CNS disease regardless of prior CNS history.

  • History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage within 6 months of enrollment.

  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.

  • History of symptomatic pulmonary embolism within 3 months of enrollment; ongoing anticoagulation is allowed if beyond 3 months.

  • Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.

  • History of allergic reactions or severe immediate hypersensitivity reaction to any of the agents used in this study or compounds of similar chemical or biologic composition.

  • Females who are pregnant or breastfeeding or female or male participants who are not willing to practice birth control from the time of consent through 6 months after the completion of CAR-T

  • In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.

  • History of autoimmune disease requiring ongoing systemic immunosuppression. Steroids are allowed up to 5mg predinosine-equivalent for adrenal insufficiency.

  • Receipt of a BCG vaccine within 12 weeks prior to Screening.

  • Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screeing.

  • Participants who are receiving any other investigational agents for this condition.

  • Patients anticipated to require canakinumab, JAK inhibitors, TNF inhibitors, and tocilizumab for non-CAR-T management of baseline autoimmune/inflammatory disease at the time of emapalumab initiation.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위화되지 않음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Cohort 1a

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Patients will receive emapalumab 3mg/kg on day -1.

FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes.

An interferon gamma (IFNγ) blocking antibody

다른 이름들:
  • 가미판트
  • 인간 항인터페론 감마(IFNγ) 단일클론항체

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

실험적: Cohort 1b

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes.

Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2.

Patients will receive emapalumab 3mg/kg on day +1.

An interferon gamma (IFNγ) blocking antibody

다른 이름들:
  • 가미판트
  • 인간 항인터페론 감마(IFNγ) 단일클론항체

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

Corticosteroid

실험적: Cohort 2a

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Patients will receive emapalumab 3mg/kg on day -1.

Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes.

An interferon gamma (IFNγ) blocking antibody

다른 이름들:
  • 가미판트
  • 인간 항인터페론 감마(IFNγ) 단일클론항체

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

실험적: Cohort 2b

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes.

Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2.

Patients will receive emapalumab 3mg/kg on day +1.

An interferon gamma (IFNγ) blocking antibody

다른 이름들:
  • 가미판트
  • 인간 항인터페론 감마(IFNγ) 단일클론항체

Alkylating agent

Purine antagonist antimetabolite

Corticosteroid

Autologous treatment

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Incidence of grade 2+ CRS per ASTCT
기간: Day -1 to 24 months post treatment

Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). All participants will be monitored and assessed for grade 2+ cytokine release syndrome (CRS) for 24 months after post treatment.

Day -1 to 24 months post treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Rate and severity of ICANS as per ASTCT
기간: 30 days

Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). The rate and severity of immune cell associated neurotoxicity syndrome (ICANS) within the first 30 days of infusion.

30 days
Objective response rate (ORR)
기간: Day -1 to 24 months post treatment

The incidence of either a complete response or a partial response by Lugano. All subjects that do not meet the criteria for an objective response by the analysis data cutoff date will be considered non-responders.

Day -1 to 24 months post treatment

기타 결과 측정

결과 측정
측정값 설명
기간
Duration of response (DOR)
기간: From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment

Among subject who experience an objective response the date of their first objective response to disease progression per Lugano or death regardless of cause. Subjects not meeting the criteria for progression or death by the analysis data cutoff date will be censored at their last evaluable disease assessment date and their response will be noted as ongoing.

From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
Progression-free Survival (PFS)
기간: From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment

The time from the CAR-T infusion date to the date of disease progression per Lugano or death from any cause. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.

From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
Overall survival (OS)
기간: From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment

The time from CAR-T infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.

From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Matthew Frigault, MD, Massachusetts General Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 9월 18일

기본 완료 (추정된)

2027년 8월 1일

연구 완료 (추정된)

2028년 8월 1일

연구 등록 날짜

최초 제출

2024년 8월 5일

QC 기준을 충족하는 최초 제출

2024년 8월 8일

처음 게시됨 (실제)

2024년 8월 12일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 6일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 1일

마지막으로 확인됨

2026년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD 공유 기간

Data can be shared no earlier than 1 year following the date of publication

IPD 공유 액세스 기준

Contact the Partners Innovations team at http://www.partners.org/innovation

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다